Based on the ADMA Biologics Inc stock forecast from 3 analysts, the average analyst target price for ADMA Biologics Inc is USD 17.50 over the next 12 months. ADMA Biologics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of ADMA Biologics Inc is Slightly Bullish , which is based on 10 positive signals and 6 negative signals. At the last closing, ADMA Biologics Inc’s stock price was USD 21.18. ADMA Biologics Inc’s stock price has changed by +11.24% over the past week, +32.71% over the past month and +434.85% over the last year.
No recent analyst target price found for ADMA Biologics Inc
No recent average analyst rating found for ADMA Biologics Inc
Company Overview ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446 Read Less
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intr...Read More
Frequently Asked Questions About ADMA Biologics Inc (ADMA) Stock
Based on ratings from 3 analysts ADMA Biologics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADMA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ADMA is USD 17.50 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
ADMA stock's Price/Earning ratio is 78.44.
Our analysis grades ADMA stock's Price / Earning ratio at F. This means that ADMA stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADMA may be a overvalued for its sector.
The last closing price of ADMA's stock was USD 21.18.
The most recent market capitalization for ADMA is USD 5.01B.
Based on targets from 3 analysts, the average taret price for ADMA is projected at USD 17.50 over the next 12 months.
This means that ADMA's stock price may go down by -17.37% over the next 12 months.
We can't find any ETFs which contains ADMA Biologics Inc's stock.
As per our most recent records ADMA Biologics Inc has 624 Employees.
ADMA Biologics Inc's registered address is 465 State Route 17, Ramsey, NJ, United States, 07446.
You can get more information about it from ADMA Biologics Inc's website at https://www.admabiologics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ADMA Biologics Inc (ADMA) Stock
Based on ratings from 3 analysts ADMA Biologics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ADMA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ADMA is USD 17.50 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
ADMA stock's Price/Earning ratio is 78.44.
Our analysis grades ADMA stock's Price / Earning ratio at F. This means that ADMA stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ADMA may be a overvalued for its sector.
The last closing price of ADMA's stock was USD 21.18.
The most recent market capitalization for ADMA is USD 5.01B.
Based on targets from 3 analysts, the average taret price for ADMA is projected at USD 17.50 over the next 12 months.
This means that ADMA's stock price may go down by -17.37% over the next 12 months.
We can't find any ETFs which contains ADMA Biologics Inc's stock.
As per our most recent records ADMA Biologics Inc has 624 Employees.
ADMA Biologics Inc's registered address is 465 State Route 17, Ramsey, NJ, United States, 07446.
You can get more information about it from ADMA Biologics Inc's website at https://www.admabiologics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ADMA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
